Special:LongPages

Longest pages

The longest articles by source size. Length is not quality, but an unusually long article is often one that should have been split.

#	Article	Source bytes	Sections	Citations
1	Lyophilisation	28,679	8	14
2	Cold chain	27,220	7	15
3	Vial	26,012	7	16
4	Temperature excursion	24,964	6	16
5	Multi-dose vial	24,688	7	13
6	Beyond-use date	23,171	7	9
7	Syringe dead space	20,968	6	10
8	Sharps disposal	20,876	6	10
9	Sigma-Aldrich (Shanghai) Trading	18,643	10	8
10	Thermo Fisher Scientific (China)	18,575	10	8
11	PolyPeptide Group (Hangzhou)	18,365	10	8
12	SinoPep	18,360	10	8
13	GenScript Peptides	17,835	10	8
14	Shenzhen Hybio Pharmaceutical	17,718	10	8
15	AmbioPharm	17,175	10	8
16	Asymchem Laboratories	17,162	10	8
17	GL Biochem (Shanghai)	16,491	10	8
18	WuXi TIDES	16,434	10	8
19	Wuhan Wansheng Biotechnology	15,851	10	8
20	Shanghai Sigma-Audley New Material Technology	15,581	10	8
21	Chinese Peptide Company	15,515	10	8
22	Hunan Aslsen Technology	15,494	10	8
23	Qingdao Sigma Chemical	15,457	10	8
24	Guangzhou JEEP Biotechnology	15,454	10	8
25	Shanghai Wibson Biotechnology	15,442	10	8
26	Xi'an Mokemei Biotechnology	15,423	10	8
27	Bachem Holding (Suzhou)	15,126	10	8
28	Nantong Guangyuan Chemical	15,116	10	8
29	ChinaPeptides	14,981	10	8
30	Hubei Jianxiang Bioscience	14,857	10	8
31	Flourishglobal Peptide Biotech	14,773	10	8
32	Sangon Biotech	14,766	10	8
33	Zhuhai Kerui Biotechnology	14,713	10	8
34	Shanghai ERP Biotechnology	14,639	10	8
35	Qingdao Saber Technology Pharmaceutical	14,594	10	8
36	Tianjin Finder Chemical	14,451	10	8
37	Glucagon-like peptide-1	12,294	6	8
38	GLP-1 receptor agonist	11,264	5	8
39	Semaglutide	10,355	5	6
40	Certificate of analysis	10,014	4	4
41	Karl Fischer titration	9,318	5	4
42	Reconstitution calculator	8,662	5	4
43	Area percent purity	8,537	3	4
44	Peptide supply chain	8,410	3	4
45	Peptide content	8,404	3	4
46	Glucose-dependent insulinotropic polypeptide	8,265	4	4
47	Blind sampling	8,193	3	4
48	Tirzepatide	8,037	4	5
49	Research use only	7,990	3	6
50	GLP-1 receptor	7,570	4	4
51	Third-party testing	7,489	4	4
52	Retatrutide	7,421	4	4
53	Incretin effect	7,358	4	5
54	Trial data comparison	7,303	4	5
55	High-performance liquid chromatography	7,231	4	4
56	Glucagon	7,074	4	4
57	Dipeptidyl peptidase-4	7,022	4	4
58	Insulin secretion	6,940	4	4
59	Peptide stability table	6,886	4	4
60	Peptide	6,813	4	4
61	Proglucagon	6,709	4	4
62	Albumin binding half-life extension	6,399	3	4
63	Insulin syringe unit conversion	6,290	4	4
64	Beta cell function	6,096	3	4
65	Liraglutide	5,967	3	4
66	Dual incretin agonist	5,851	3	4
67	Amylin	5,795	3	4
68	Adverse effects of GLP-1 receptor agonists	5,791	3	5
69	Reconstitution of lyophilised peptides	5,761	3	4
70	Exenatide	5,754	3	4
71	CagriSema	5,687	3	4
72	Purity claim inflation	5,660	3	4
73	Peptide synthesis	5,649	3	4
74	Orforglipron	5,647	3	4
75	Mass spectrometry	5,612	3	4
76	Satiety signalling	5,593	3	4
77	Gastric emptying	5,565	3	4
78	STEP trial programme	5,534	3	4
79	Peptide aggregation	5,516	3	4
80	Reverse-phase HPLC	5,499	3	4
81	Dulaglutide	5,490	3	4
82	Counterfeit peptide	5,488	3	4
83	Survodutide	5,445	3	4
84	Test report forgery	5,391	3	4
85	Solid-phase peptide synthesis	5,359	3	4
86	Analytical method validation	5,342	3	4
87	Bacterial endotoxin test	5,317	3	4
88	Lot traceability	5,317	3	4
89	Subcutaneous injection	5,293	3	4
90	Missed dose	5,277	3	4
91	Deamidation	5,263	3	4
92	Arcuate nucleus	5,251	3	4
93	Amylin receptor agonist	5,245	3	4
94	Janoshik Analytical	5,235	3	4
95	Reference standard	5,217	3	4
96	USP General Chapter 85	5,180	3	4
97	SELECT trial	5,171	3	4
98	Chain of custody	5,157	3	4
99	SUSTAIN trial programme	5,153	3	4
100	Good manufacturing practice	5,123	3	4